<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02398994</url>
  </required_header>
  <id_info>
    <org_study_id>RJ115/N065</org_study_id>
    <secondary_id>2014-002335-34</secondary_id>
    <secondary_id>11/129/148</secondary_id>
    <secondary_id>12127581</secondary_id>
    <nct_id>NCT02398994</nct_id>
  </id_info>
  <brief_title>A Multicentre randomiSed Controlled TRial of IntraVEnous Immunoglobulin Versus Standard Therapy for Transverse Myelitis</brief_title>
  <acronym>STRIVE</acronym>
  <official_title>A Multicentre randomiSed Controlled TRial of IntraVEnous Immunoglobulin (IVIg) Versus Standard Therapy for the Treatment of Transverse Myelitis in Adults and Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Guy's and St Thomas' NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>King's College London</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Barts and the London School of Medicine and Dentistry</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cardiff University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University College, London</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>King's College Hospital NHS Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Great Ormond Street Hospital for Children NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Barts &amp; The London NHS Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Alder Hey Children's NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Walton Centre NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Oxford University Hospitals NHS Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Birmingham Women's and Children's NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital Birmingham NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cardiff and Vale University Health Board</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>North Bristol NHS Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospitals Bristol and Weston NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Manchester University NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Salford Royal NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital Southampton NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Newcastle-upon-Tyne Hospitals NHS Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Nottingham University Hospitals NHS Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>NHS Lothian</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Guy's and St Thomas' NHS Foundation Trust</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This multi-center randomized controlled trial evaluates if the addition of intravenous&#xD;
      immunoglobulin to standard treatment of corticosteroids improves outcome in children and&#xD;
      adults with first episode of Transverse Myelitis of Neuro-myelitis optica. Half of&#xD;
      participants will receive corticosteroids alone, whilst the other half will receive&#xD;
      corticosteroids plus intravenous immunoglobulin.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Transverse myelitis (TM) is a severe demyelinating condition predominantly affecting young&#xD;
      people, which causes significant long-term disability in approximately one third. Current&#xD;
      initial treatment is with corticosteroids, although evidence for their use is based on&#xD;
      extrapolation from trials in adult multiple sclerosis relapses. In view of the severity of&#xD;
      the condition, additional treatments have been trialed.&#xD;
&#xD;
      Intravenous immunoglobulin (IVIG) is often used as second-line treatment in&#xD;
      steroid-unresponsive central nervous system demyelination, although evidence for its efficacy&#xD;
      is limited to small case series and case reports. Randomized controlled trials have&#xD;
      demonstrated that IVIG reduces inflammation and enhances remyelination in a number of&#xD;
      neurological conditions, although there have been no randomized controlled trials testing its&#xD;
      use in adults and children with TM.&#xD;
&#xD;
      This study will evaluate if additional and early treatment with IVIG is of extra benefit in&#xD;
      TM when compared to the current standard therapy of intravenous steroids alone.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Continued effort did not successfully increase recruitment into the study.&#xD;
  </why_stopped>
  <start_date>March 2015</start_date>
  <completion_date type="Actual">March 2016</completion_date>
  <primary_completion_date type="Actual">March 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>2 points or greater improvement on the American Spinal Injury Association (ASIA) Impairment scale (classified A-E)</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in ASIA motor scale (0-100) and ASIA sensory scale (0-112)</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Kurtzke's expanded disability status scale (EDSS) measured with Neurostatus scoring</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EQ-5D-Y (for patients aged 8-12 years at presentation)</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EQ-5D-5L (for patients aged 13 years or over at presentation)</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>International Spinal Cord Injury (SCI) Quality of Life Basic Data Set (for patients aged 13 years or over at presentation)</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Client Service Receipt Inventory (CSRI)</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>International SCI Bladder/Bowel Data Set (for patients aged 13 years or over at presentation)</measure>
    <time_frame>6 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Paediatric Quality of Life Inventory™ (PedsQL) Parent Report for Toddlers (for patients aged 2-4 years at presentation)</measure>
    <time_frame>6 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Paediatric Quality of Life Inventory™(PedsQL) Parent Report for Young Children (for patients aged 5-7 years at presentation)</measure>
    <time_frame>6 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>International SCI Pain Basic Data Set (for patients ages 13 years or over at presentation)</measure>
    <time_frame>6 months</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">2</enrollment>
  <condition>Myelitis, Transverse</condition>
  <condition>Neuromyelitis Optica</condition>
  <arm_group>
    <arm_group_label>Intravenous Methylprednisolone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Paediatric patients - 30mg/kg or 500mg/m2 up to a maximum daily dose of 1g/day for 5 days.&#xD;
Adult patients - 1g/day for 5 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intravenous Immunoglobulin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Paediatric patients &lt;41.2kg - total dose of 2g/kg in divided doses over 2 days.&#xD;
All other patients - total dose of 2g/kg in divided doses over 5 days.&#xD;
PLUS Intravenous Methylprednisolone&#xD;
Pediatric patients - 30mg/kg or 500mg/m2 up to a maximum daily dose of 1g/day for 5 days.&#xD;
Adult patients - 1g/day for 5 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intravenous Methylprednisolone</intervention_name>
    <arm_group_label>Intravenous Immunoglobulin</arm_group_label>
    <arm_group_label>Intravenous Methylprednisolone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intravenous Immunoglobulin</intervention_name>
    <arm_group_label>Intravenous Immunoglobulin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of&#xD;
&#xD;
        EITHER acute first onset transverse myelitis (using the TM Consortium Working Group 2002&#xD;
        criteria) - patients must fulfill all of the following criteria:&#xD;
&#xD;
          -  Sensory, motor, or autonomic dysfunction attributable to spinal cord disease&#xD;
&#xD;
          -  Bilateral signs and/or symptoms (not necessarily symmetric)&#xD;
&#xD;
          -  Sensory level (except in young children &lt;5 years where this is difficult to evaluate)&#xD;
&#xD;
          -  Lack of MRI brain criteria consistent with multiple sclerosis&#xD;
&#xD;
          -  Progression to nadir between 4 h and 21 days&#xD;
&#xD;
        OR first presentation of neuromyelitis optica (using standardised criteria) - patients must&#xD;
        fulfil both absolute criteria:&#xD;
&#xD;
          -  Optic neuritis&#xD;
&#xD;
          -  Acute myelitis, plus two out of three supportive criteria (as Aquaporin 4 antibody&#xD;
             (AQP4) is often not available acutely, only the first two supportive criteria would be&#xD;
             applied),&#xD;
&#xD;
          -  Brain MRI not meeting criteria for Multiple Sclerosis (MS) at disease onset&#xD;
&#xD;
          -  Spinal cord MRI with contiguous T2-weighted signal abnormality extending over three or&#xD;
             more vertebral segments, indicating a relatively large lesion in the spinal cord&#xD;
&#xD;
          -  AQP4 seropositive status&#xD;
&#xD;
               -  ASIA Impairment Score of A-C&#xD;
&#xD;
               -  Randomisation to occur no later than day 5 of steroids, and, if definitely known,&#xD;
                  within 21 days from symptom onset.&#xD;
&#xD;
               -  Give assent (8-16 years)/consent to participate in the trial&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Contraindication to IVIG as stated in the summary of product characteristics (SmPC),&#xD;
             or receiving IVIG for other reasons&#xD;
&#xD;
          -  Previously known systemic autoimmune disease (e.g. systemic lupus erythematosus) or&#xD;
             any evidence of systemic inflammation during current presentation.&#xD;
&#xD;
          -  Direct infectious aetiology (e.g. varicella zoster)&#xD;
&#xD;
          -  Previous episode of central nervous system (CNS) inflammatory demyelination&#xD;
&#xD;
          -  Acute disseminated encephalomyelitis (ADEM)&#xD;
&#xD;
          -  Other causes of myelopathy not thought to be due to myelitis (e.g. nutritional,&#xD;
             ischaemic, tumour etc.)&#xD;
&#xD;
          -  Other disease which would interfere with assessment of outcome measures&#xD;
&#xD;
          -  Known pregnancy&#xD;
&#xD;
          -  Circumstances which would prevent follow-up for 12 month&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ming Lim, MB, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Guy's and St Thomas' NHS Foundation Trust</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Birmingham Children's Hospital NHS Foundation Trust</name>
      <address>
        <city>Birmingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospitals Birmingham NHS Foundation Trust</name>
      <address>
        <city>Birmingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Bristol NHS Trust</name>
      <address>
        <city>Bristol</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Bristol NHS Foundation Trust</name>
      <address>
        <city>Bristol</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardiff and Vale University Health Board</name>
      <address>
        <city>Cardiff</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NHS Lothian</name>
      <address>
        <city>Edinburgh</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alder Hey Children's NHS Foundation Trust</name>
      <address>
        <city>Liverpool</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Walton Centre NHS Foundation Trust</name>
      <address>
        <city>Liverpool</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Great Ormond Street Children's Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Guy's and St Thomas' NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>King's College Hospital NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of London and Bart's Health NHS Trust</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Manchester University Hospitals NHS Foundation Trust</name>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Newcastle-upon-Tyne Hospitals NHS Trust</name>
      <address>
        <city>Newcastle</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nottingham University Hospitals NHS Trust</name>
      <address>
        <city>Nottingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oxford University Hospitals NHS Trust</name>
      <address>
        <city>Oxford</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Salford Royal NHS Foundation Trust</name>
      <address>
        <city>Salford</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Southampton NHS Foundation Trust</name>
      <address>
        <city>Southampton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://www.myelitis.org.uk/strive-clinical-trial.html</url>
    <description>TM Society Trial Information</description>
  </link>
  <link>
    <url>http://www.nets.nihr.ac.uk/projects/hta/11129148</url>
    <description>National Institute for Health Research Portfolio</description>
  </link>
  <verification_date>July 2016</verification_date>
  <study_first_submitted>March 23, 2015</study_first_submitted>
  <study_first_submitted_qc>March 25, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 26, 2015</study_first_posted>
  <last_update_submitted>July 18, 2016</last_update_submitted>
  <last_update_submitted_qc>July 18, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 20, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Clinical Trials Unit</keyword>
  <keyword>Pediatric</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myelitis</mesh_term>
    <mesh_term>Myelitis, Transverse</mesh_term>
    <mesh_term>Neuromyelitis Optica</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Immunoglobulins, Intravenous</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>gamma-Globulins</mesh_term>
    <mesh_term>Rho(D) Immune Globulin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

